Lupin to acquire German based Temmler Pharma's speciality based portfolio
Just after announcing its recent acquisition of Gavis, Lupin has made a recent announcement of acquiring the speciality product portfolio of Temmler Pharma, thus strengthening its speciality business manifold After its recent announcement of strengthening its position in the US market, through its acquisition of Gavis as reported by the Medical Dialogues team earlier, the Mumbai based Lupin...
Login or Register to read the full article
Just after announcing its recent acquisition of Gavis, Lupin has made a recent announcement of acquiring the speciality product portfolio of Temmler Pharma, thus strengthening its speciality business manifold
After its recent announcement of strengthening its position in the US market, through its acquisition of Gavis as reported by the Medical Dialogues team earlier, the Mumbai based Lupin seems to be an acquisition spree to strengthen its position in the speciality drugs business. Lupin is set to acquire the speciality product portfolio of Temmler Pharma, a German base company .
The company has recently reported that it has entered into a strategic asset purchase agreement with Temmler Pharma, a part of the Aenova Group, for the acquisition. Based in Marburg (Germany), Temmler has a specialty portfolio of 13 products including key Central Nervous System products and specialty products that address rare disease areas like Myasthenia Gravis, Huntington disease as well as fast-growing dermatology products for anti-wart treatment.
Further reported by PTI,
"Temmler is a profitable pharmaceutical player backed by a strong and experienced management team that is also taken on and which will strongly support our future growth plans," Lupin, President- Europe and Head of Inhalation Strategy, Maurice Chagnaud said.
Aenova Group CFO, Frank Elsen said Lupin is perfectly poised to take Temmler's product portfolio and its growth forward.
"We are extremely optimistic about this strategic agreement which allows us to concentrate on our core business. As a leading CDMO we are proud to continue to manufacture and supply at highest quality all related products to our partner Lupin," he added.
Lupin is on a spree to acquire pharmaceutical firms globally.
Earlier this month, the company acquired Russia's Biocom, marking its entry into one of the world's top drug markets. In May, Lupin strengthened its position in the Latin American market when it entered the Brazilian market by acquiring Medquimica Industria Farmaceutica SA.
Last year, Lupin had acquired Laboratories Grin SA in Mexico, the fourth largest drugmaker in that country.
After its recent announcement of strengthening its position in the US market, through its acquisition of Gavis as reported by the Medical Dialogues team earlier, the Mumbai based Lupin seems to be an acquisition spree to strengthen its position in the speciality drugs business. Lupin is set to acquire the speciality product portfolio of Temmler Pharma, a German base company .
The company has recently reported that it has entered into a strategic asset purchase agreement with Temmler Pharma, a part of the Aenova Group, for the acquisition. Based in Marburg (Germany), Temmler has a specialty portfolio of 13 products including key Central Nervous System products and specialty products that address rare disease areas like Myasthenia Gravis, Huntington disease as well as fast-growing dermatology products for anti-wart treatment.
Further reported by PTI,
"Temmler is a profitable pharmaceutical player backed by a strong and experienced management team that is also taken on and which will strongly support our future growth plans," Lupin, President- Europe and Head of Inhalation Strategy, Maurice Chagnaud said.
Aenova Group CFO, Frank Elsen said Lupin is perfectly poised to take Temmler's product portfolio and its growth forward.
"We are extremely optimistic about this strategic agreement which allows us to concentrate on our core business. As a leading CDMO we are proud to continue to manufacture and supply at highest quality all related products to our partner Lupin," he added.
Lupin is on a spree to acquire pharmaceutical firms globally.
Earlier this month, the company acquired Russia's Biocom, marking its entry into one of the world's top drug markets. In May, Lupin strengthened its position in the Latin American market when it entered the Brazilian market by acquiring Medquimica Industria Farmaceutica SA.
Last year, Lupin had acquired Laboratories Grin SA in Mexico, the fourth largest drugmaker in that country.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd